

11-23-01

A

Attorney Docket No.: 6263.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Commissioner for Patents
Washington, DC 20231

Express Mail Label No. EL636737726US
Date of Deposit. November 16, 2001

Sir:

This is a request for filing a patent application under 37 C.F.R. 1.53(b) of

Applicant(s): Anker Steen Jorgensen et al.

Title: Glucagon Antagonists/Inverse Agonists

81 pages of specification -0- sheet of Formal Drawings

3 sheets of Declaration and Power of Attorney

1 sheet of Abstract

[x] The filing fee is calculated as follows:

Basic Fee:	\$ 740.00
Total Claims: $51-20 = 31 \times 18 =$	\$ 558.00
Independent Claims: $1 - 3 = 0 \times 84 =$	\$ -0-
Total Fee:	\$ 1,298.00

Priority of Danish application no. PA 2000 01733 filed on November 17, 2000 is claimed under 35 U.S.C. 119. Certified copies will be submitted at a later date.


Priority of U.S. provisional application no. 60/252,322 filed on November 20, 2000 is claimed under 35 U.S.C. 119.

Address all future communications to Reza Green, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$1,298.00, and any other applicable fees, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: November 16, 2001


Richard W. Bork Reg. No. 36,459
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
EXPRESS MAIL CERTIFICATE**

Box Patent Application
Commissioner for Patents
Washington, DC 20231

Re: U.S. Patent Application for
Title: Glucagon Antagonists/Inverse Agonists
Applicants: Anker Steen Jørgensen et al.

Sir:

Express Mail Label No. **EL636737726US**

Date of Deposit: **November 16, 2001**


I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application (81 pages of Spec/1 sheet abstract/)
3. Unexecuted Combined Declaration and Power of Attorney
4. Preliminary Amendment

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, DC 20231.

Sylvia Gonzalez

(Name of person mailing paper(s) or fee)



(Signature of person mailing paper(s) or fee)

Mailing Address:
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123